جميع الدراسات
التوظيفالمرحلة 1، المرحلة 2تدخلي

Phase 1/2 Study of Mirdametinib + Vinblastine for Newly Diagnosed/Previously Untreated PLGG + Activation of MAPK

This research study is for children and young people aged 2 to 25 who have been diagnosed with a type of brain tumour called paediatric low-grade glioma. We are testing a new treatment that combines a drug called mirdametinib, taken by mouth, with vinblastine, a chemotherapy drug given through a vein. The main goal is to find the safest and most effective dose of this combination. We'll also be looking at how well the treatment helps shrink the tumour and keeps it from growing. This study is for patients whose tumours have a specific genetic change that activates a pathway called MAPK. We hope this new approach could offer a better way to treat this condition.

نظرة سريعة

الحالة
التوظيف
المرحلة
المرحلة 1، المرحلة 2
الراعي
St. Justine's Hospital
الهدف من التسجيل
50
ابدأ
12 يناير 2026
التاريخ المتوقع للانتهاء
01 Apr 2033

ما هو موضوع هذه الدراسة؟

This study is particularly for children and young people, from 2 to 25 years old, who have a type of brain tumour called paediatric low-grade glioma (PLGG). We are exploring a new treatment approach that brings together two different medicines: mirdametinib and vinblastine. Mirdametinib is a newer type of drug that targets specific pathways in the body that can cause cancer to grow. Vinblastine is a more traditional chemotherapy drug that works by stopping cancer cells from dividing.

The main idea behind this study is to see if using these two drugs together is a safe and effective way to treat PLGG, especially for tumours that have a specific genetic change (activating the MAPK pathway). We call this a 'Phase 1/2' study, which means we'll first focus on finding the best dose of the combination that is both safe and works well. Once we've found that dose, we'll then treat more patients to see how effective it is in controlling the tumour's growth.

This research is important because it could lead to new and better treatment options for children and young people with PLGG. We are carefully studying how the body reacts to these medicines and how they affect the tumour, always keeping patient safety and well-being as our top priority.

النقاط الرئيسية

  • This study is for children and young people aged 2-25 with specific types of low-grade brain tumours.
  • It tests a new drug (mirdametinib) combined with an existing chemotherapy (vinblastine).
  • The initial aim is to find the safest and most effective dose of the combination.
  • Patients receive treatment for over a year, followed by long-term follow-up.
  • The study hopes to find a better treatment option for this cancer.

من قد يكون مؤهلاً؟

This study is looking for children and young people between the ages of 2 and 25 years old. To join, you must have been recently diagnosed with paediatric low-grade glioma, or your tumour hasn't been treated with other medicines or radiotherapy before. Importantly, your tumour needs to show a specific genetic change (called activation of the MAPK pathway, but not a BRAF V600E mutation) or be linked to conditions like neurofibromatosis type 1 (NF1) or have a specific KIAA1549-BRAF fusion.

There are also some general health requirements. You'll need to be well enough to take part, have certain body measurements, and your organs (like your heart and blood) need to be working properly as shown by tests. You must also be able to take medication by mouth. If you are able to have children, you and your doctor will need to discuss birth control methods.

Some things would mean you couldn't join. For example, if you're already receiving other experimental treatments, have a specific heart condition, another serious cancer, or a certain type of genetic change (BRAF V600E mutation) in your tumour. Also, if your blood pressure is too high for your age, or if you can't take medicines by mouth, you wouldn't be able to participate.

هل يمكن أن تناسبك هذه الدراسة؟

أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.

  1. Are you between 2 and 25 years old?
  2. Do you have a newly diagnosed brain tumour (paediatric low-grade glioma) that hasn't been treated before?
  3. Does your tumour have a specific genetic change (MAPK pathway activation, but not BRAF V600E mutation)?
  4. Are you able to swallow medication by mouth?
  5. Are your heart, kidneys, and blood counts generally healthy?
أجب عن كل سؤال لترى نتيجتك.

ماذا يتضمن المشاركة؟

If you join this study, it will involve a few different stages. First, a small group of patients will help us find the right dose of the two medicines, mirdametinib and vinblastine, that works best and is safe. This involves carefully increasing the dose within safe limits until the best combination is found.

You would take mirdametinib by mouth twice a day, every day, for about a year (13 cycles, with each cycle lasting 28 days). The vinblastine would be given through a vein once a week for a longer period, around 17 cycles. The dose of vinblastine will be adjusted based on what is found to be the safest and most effective for everyone. If you experience side effects, the doctors might reduce the dose of your medication.

Throughout the study, you'll have regular hospital visits for check-ups, blood tests, and scans (like an MRI with contrast) to see how you're responding to the treatment and to monitor for any side effects. After your treatment finishes, you'll continue to have follow-up visits every six months for three years to see how you're doing in the longer term. In total, we plan for 50 patients to take part in this study.

المخاطر والفوائد المحتملة

Taking part in any clinical study has potential benefits and risks. A potential benefit of this study is that the combination of mirdametinib and vinblastine might be more effective in treating your low-grade glioma than existing treatments, potentially slowing its growth or shrinking it. However, because these are medicines, there's a risk of side effects. These could include feeling unwell, changes in blood counts, or other reactions, and the study team will carefully monitor you for these. You have the right to withdraw from the study at any time, for any reason, without it affecting your medical care.

المواقع (5)

  • Stollery Children's Hospital
    الرمز البريدي المؤكد
    إدمونتون، كندا· التوظيف
  • Childrens and Womens Health Centre of British Columbia - British Columbia Childrens Hospital
    الرمز البريدي المؤكد
    فانكوفر، كندا· التوظيف
  • Children's Hospital, London Health Sciences Centre
    الرمز البريدي المؤكد
    لندن، كندا· التوظيف
  • مستشفى الأطفال المرضى
    الرمز البريدي المؤكد
    تورونتو، كندا· التوظيف
  • CHU Sainte-Justine
    الرمز البريدي المؤكد
    مونتريال، كندا· التوظيف

أسئلة شائعة

What is paediatric low-grade glioma?

It's a type of slow-growing brain tumour that affects children and young people.

What do 'mirdametinib' and 'vinblastine' do?

Mirdametinib is a new drug targeting how cancer grows, and vinblastine is a chemotherapy drug that kills cancer cells.

Will I get both drugs?

Yes, if you're in the treatment part of the study, you will receive mirdametinib by mouth and vinblastine through a vein.

كم من الوقت سأكون في الدراسة؟

Treatment can last for over a year, followed by three years of check-up visits every six months.

Can I stop the study if I want to?

Yes, you can choose to leave the study at any time, without affecting your regular medical care.

كيفية معرفة المزيد

Sébastien Perreault, M.D, FRCPC

تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.

هل أنت مهتم بالمشاركة؟

سجل اهتمامك

شارك تفاصيلك وفريق البحث لـ "Phase 1/2 Study of Mirdametinib + Vinblastine for Newly Diag… "سيتواصل معك إذا كنت مؤهلاً. تحدث دائمًا إلى طبيبك قبل الموافقة على المشاركة.

نقاش

مناقشة المجتمع

مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.